Commentary

Commentary: Overcoming the dangerous narrative of computed tomography screening for lung cancer

Disclosures: Dr Stiles is a consultant for AstraZeneca, Pfizer, and Flame Biosciences; has been a part of advisory boards/received speaking fees for Bristol Myers Squibb, Genentech, Ribon Therapeutics, and PeerView; and is a board member of the Lung Cancer Research Foundation.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.